No Fanfare For US Approval Of Sanofi's GLP-1 Adlyxin
Sanofi has secured US approval for its a once-daily mealtime GLP-1 injection Adlyxin (lixisenatide) as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes, but as the sixth GLP-1 product to enter this market the drug is unlikely to gain a strong foothold.
You may also be interested in...
"A somewhat challenging quarter," was how Sanofi CEO Olivier Brandicourt described the second three months of 2016, but analysts say there were no surprises in the downward trajectory of Sanofi's fortunes. There was also little news on Sanofi's pursuit of Medivation.
The Scrip 100 universe gathers FY 2019 financial performance data and compares the activities of the Top 100 biopharma businesses, ranked by pharma sales. Here In Vivo breaks out the Top 10 in the league table. Which big pharma holds the top spot this year?
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.